MedTrace Logo

Tenecteplase (TNK) for Loculated Pleural Effusions in Patients With Malignancy

NCT01580618 · Status: TERMINATED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2026-04-14

Study results available
· View outcomes & findings →

Summary

The objective of the study is to determine the safety and efficacy of TNK infusion for the treatment of loculated pleural effusions in patients with known malignancy compared to normal saline infusion.

Conditions

  • Pleural Effusion

Interventions

DRUG

normal saline

Injection of 60 ml normal saline twice a day for three days using the existing chest tube.

DRUG

TNK (Tenecteplase)

Injection of 4 mg of TNK with 59 ml normal saline into the existing chest tube twice a day for three days.

Sponsors & Collaborators

Principal Investigators

  • Hyo-Chun Yoon, MD · Kaiser Permanente

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2011-09-30
Completion
2011-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01580618 on ClinicalTrials.gov